Clinical Trial Update: Erlotinib and Cisplatin in Treating Patients With Recurrent or Metastatic Head and Neck Cancer [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 trial evaluating erlotinib in combination with cisplatin for recurrent or metastatic head and neck cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer

Drugs mentioned

• CISPLATIN (cisplatin)
• ERLOTINIB (Erlotinib)

Snippet

Sponsor: University Health Network, Toronto | Conditions: Head and Neck Cancer | Phase 1, Phase 2 | Status: COMPLETED